Citable filing context
TECH's research view summarizes recent SEC filing context, starting with acquisition from Sep 23, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 23, 2026 | acquisition | Bio-Techne shareholders approved the company's acquisition by Merck KGaA, Darmstadt, Germany. |
| Sep 14, 2026 | acquisition | Bio-Techne provided supplemental proxy disclosures regarding its pending acquisition by Merck KGaA following shareholder litigation. |
| Aug 12, 2026 | earnings | Bio-Techne reported fiscal 2026 fourth quarter revenue of $321.2 million and full year revenue of $1.2 billion. |
| Jun 25, 2026 | Guidance: cost_synergies | not reported to 140.00 |
| Aug 24, 2026 | business | Bio-Techne Corporation (NASDAQ: TECH) develops and manufactures life science reagents, analytical instruments, and diagnostic tools for the bioprocessing, research, and clinical markets. The business operates through two segments: Protein Sciences and Diagnostics and Spatial Biology. The Protein Sciences segment generates approximately 72% of net sales, offering biological reagents, cytokines, cGMP-grade proteins, and automated western blot and ELISA platforms. Key brands include R&D Systems, ProteinSimple, Tocris Biosciences, and Novus Biologicals. This segment serves academic, pharmaceutical, and cell and gene therapy customers directly and through distributors like Thermo Fisher Scientific. To bolster its cell therapy presence, Bio-Techne holds a minority stake in cell culture device manufacturer Wilson Wolf, with a commitment to acquire full ownership by calendar year 2027. The Diagnostics and Spatial Biology segment accounts for 28% of net sales, providing single-cell tissue profiling, spatial genomics, and oncology diagnostics. Key brands include Advanced Cell Diagnostics, Asuragen, and Lunaphore, whose COMET instrument automates hyperplex tissue analysis. Sales occur via original equipment manufacturer (OEM) agreements, direct channels, and clinical laboratory networks. Strategic growth centers on spatial biology, automated proteomic workflows, and biomanufacturing inputs. Operational risks include reliance on single-source suppliers for specific biological and electronic components, mitigated by safety stock and dual-sourcing initiatives. Customer concentration risk is low, with no single customer accounting for more than 10% of revenue. |
| Aug 24, 2026 | mda | Bio-Techne agreed to be acquired by Merck KGaA on June 25, 2026, for $73.00 per share in cash, with closing targeted for late 2026 or early 2027. For fiscal 2026, net sales were flat at $1.22 billion with 0% organic growth, as a 2% favorable foreign currency impact was offset by a 2% headwind from held-for-sale assets. Protein Sciences net sales increased 1% to $874.6 million (-1% organic), negatively impacted by pricing pressures and product mix. Diagnostics and Spatial Biology net sales declined 3% to $336.4 million (+4% organic), slowed by the Exosome Diagnostics divestiture. Consolidated adjusted gross margin contracted 80 basis points to 69.6% due to product mix. While GAAP pre-tax earnings rose 148% to $240.7 million due to non-recurring prior-year impairment charges and legal costs, adjusted net earnings declined 1% to $303.3 million. Operating cash flow reached $292.1 million, ending fiscal 2026 with $264.7 million in cash and available-for-sale investments and $200.0 million in credit facility debt. A key long-term financial commitment includes a forecasted $1 billion payment between fiscal 2027 and fiscal 2028 to purchase the remaining 80.1% ownership stake in Wilson Wolf. |
| Aug 24, 2026 | risk_factors | Bio-Techne’s near-term outlook is heavily influenced by its pending acquisition by Merck KGaA for $73.00 per share, expected to close by early 2027. This transaction restricts ordinary operations, risks key employee attrition, and carries a $230.5 million termination fee if aborted. Independently, the company’s growth strategy relies on integrating complex acquisitions like Lunaphore and Wilson Wolf, which exposes it to integration delays and goodwill impairment. In its core Protein Sciences and Diagnostics and Spatial Biology segments, Bio-Techne faces intense competition from multinational corporations and low-cost Asian manufacturers. Operational risks include a reliance on sole-source suppliers, animal-derived raw materials, and concentrated manufacturing in earthquake- and drought-prone California. Financially, the company is exposed to foreign currency fluctuations and obligations under a $1 billion revolving credit facility, with $200 million currently drawn. Furthermore, Bio-Techne operates under stringent regulatory frameworks, including FDA Quality System Regulations, the European Union’s In Vitro Diagnostic Regulation (EU IVDR), and strict data privacy laws like GDPR and HIPAA. Finally, macroeconomic headwinds, such as fluctuating government research funding, drug price negotiations, and persistent US-China tariffs, threaten to compress margins and disrupt global supply chains. |
Source: SEC EDGAR filing text and events; period Sep 23, 2026; filed Sep 23, 2026.
TECH company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.